Arenavirus monoclonal antibodies and uses

An antigen-binding composition comprising a neutralizing antibody or neutralizing antigen-binding antibody fragment thereof specific to glycoprotein 1 (GP1), glycoprotein 2 (GP2), glycoprotein precursor (GPC), or full-length glycoprotein (GP) of Lassa virus (LASV), wherein the antibody or antibody fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH and VL each comprising complementarity determining regions CDR1, CDR2 and CDR3 selected from the group consisting of:

• (a) a VH CDR1 of SEQ ID NO:
• 71, a VH CDR2 of SEQ ID NO:
• 72, a VH CDR3 of SEQ ID NO:
• 73, a VL CDR1 of SEQ ID NO:
• 117, a VL CDR2 of sequence Trp Ala Ser, and a VL CDR3 of SEQ ID NO:
• 118;
• (b) a VH CDR1 of SEQ ID NO:
• 74, a VH CDR2 of SEQ ID NO:
• 75, a VH CDR3 of SEQ ID NO:
• 76, a VL CDR1 of SEQ ID NO:
• 119, a VL CDR2 of sequence Glu Val Lys, and a VL CDR3 of SEQ ID NO:
• 120;
• (c) a VH CDR1 of SEQ ID NO:
• 77, a VH CDR2 of SEQ ID NO:
• 78, a VH CDR3 of SEQ ID NO:
• 79, a VL CDR1 of SEQ ID NO:
• 121, a VL CDR2 of sequence Asp Ala Ser, and a VL CDR3 of SEQ ID NO:
• 122;
• (d) a VH CDR1 of SEQ ID NO:
• 80, a VH CDR2 of SEQ ID NO:
• 81, a VH CDR3 of SEQ ID NO:
• 82, a VL CDR1 of SEQ ID NO:
• 123, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO:
• 124;
• (e) a VH CDR1 of SEQ ID NO:
• 83, a VH CDR2 of SEQ ID NO:
• 84, a VH CDR3 of SEQ ID NO:
• 85, a VL CDR1 of SEQ ID NO:
• 125, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO:
• 126;
• (f) a VH CDR1 of SEQ ID NO:
• 86, a VH CDR2 of SEQ ID NO:
• 87, a VH CDR3 of SEQ ID NO:
• 88, a VL CDR1 of SEQ ID NO:
• 127, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO:
• 128;
• (g) a VH CDR1 of SEQ ID NO:
• 89, a VH CDR2 of SEQ ID NO:
• 90, a VH CDR3 of SEQ ID NO:
• 91, a VL CDR1 of SEQ ID NO:
• 129, a VL CDR2 of sequence Glu Val Arg, and a VL CDR3 of SEQ ID NO:
• 130;
• (h) a VH CDR1 of SEQ ID NO:
• 92, a VH CDR2 of SEQ ID NO:
• 93, a VH CDR3 of SEQ ID NO:
• 94, a VL CDR1 of SEQ ID NO:
• 131, a VL CDR2 of sequence Glu Val Ser, and a VL CDR3 of SEQ ID NO:
• 132;
• (i) a VH CDR1 of SEQ ID NO:
• 95, a VH CDR2 of SEQ ID NO:
• 96, a VH CDR3 of SEQ ID NO:
• 97, a VL CDR1 of SEQ ID NO:
• 133, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO:
• 134;
• (j) a VH CDR1 of SEQ ID NO:
• 101, a VH CDR2 of SEQ ID NO:
• 102, a VH CDR3 of SEQ ID NO:
• 103, a VL CDR1 of SEQ ID NO:
• 137, a VL CDR2 of sequence Gln Ala Ser, and a VL CDR3 of SEQ ID NO:
• 138;
• (k) a VH CDR1 of SEQ ID NO:
• 104, a VH CDR2 of SEQ ID NO:
• 105, a VH CDR3 of SEQ ID NO:
• 106, a VL CDR1 of SEQ ID NO:
• 139, a VL CDR2 of sequence Gly Ala Ser, and a VL CDR3 of SEQ ID NO:
• 140;
• (l) a VH CDR1 of SEQ ID NO:
• 107, a VH CDR2 of SEQ ID NO:
• 108, a VH CDR3 of SEQ ID NO:
• 109, a VL CDR1 of SEQ ID NO:
• 141, a VL CDR2 of sequence Gly Ala Tyr, and a VL CDR3 of SEQ ID NO:
• 142;
• and
• (m) a VH CDR1 of SEQ ID NO:
• 110, a VH CDR2 of SEQ ID NO:
• 111, a VH CDR3 of SEQ ID NO:
• 112, a VL CDR1 of SEQ ID NO:
• 143, a VL CDR2 of sequence Ala Ala Val, and a VL CDR3 of SEQ ID NO:
• 144.